A recent study published in the journal Psychopharmacology discovered that psilocybin-assisted treatment (PCT) effectively reduces symptoms of major depressive disorder (MDD) even after 12 months. Johns Hopkins University researchers conducted this study, closely monitoring and evaluating 24 participants who underwent PCT for MDD. These participants were evaluated at multiple intervals including baseline, 4 weeks, 12 weeks, and finally at the one-year mark following their treatment.
The study’s findings revealed that participants who received PCT experienced a significant decrease in MDD symptoms at all measurement intervals. Specifically, at the 12-month follow-up, those who underwent PCT had an average MADRS score of 10, indicating a normal range. Conversely, the participants receiving standard care treatment obtained an average MADRS score of 18, still considered within the moderate range.
The study also uncovered that individuals who underwent PCT experienced a notable enhancement in their overall quality of life after 12 months. These same participants reported feeling more connected to others, intensely motivated, and hopeful about what lies ahead.
These findings indicate that PCT shows promise as a new treatment for MDD. Although PCT is relatively recent, further research is necessary to validate these findings. Nonetheless, the results of this study suggest that PCT holds potential as a safe and effective approach to treating MDD.
The study uncovered that PCT is beneficial for MDD. Additionally, participants showed a favorable tolerance to PCT, with no reports of serious adverse events. The most commonly reported side effects among participants were mild and temporary, including headache, nausea, and anxiety.
The results of this study indicate that PCT shows promise as a new treatment for MDD. It is both safe and effective, with good tolerability. However, further research is necessary to validate these findings. Nevertheless, PCT could emerge as a valuable treatment option for individuals suffering from MDD.
References:
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Psychopharmacology. https://doi.org/10.1177/02698811211073759
Related Content
